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The rate limiting step in translating normal and pathologi-
cal human genetic variations into a deeper understanding
of which are functionally relevant, and the development of
genetically defined disease models that can speed up and
rationalize the discovery of novel targeted therapies, now
lies firmly with our ability to quickly and precisely alter
any sequence in the human genome, just as we have been
able to do in mice and other lower organisms for many
years. However, routinely altering any user-defined endo-
genous DNA sequence in somatic human cells has been
historically challenging due to their uniformly low levels of
homologous recombination.
Horizon’s GENESIS™ gene-editing platform [http://
www.horizondiscovery.com] uses the unique ability of
targeted recombinant adeno-associated viral (rAAV) vec-
tors to naturally stimulate and piggyback on the high-
fidelity homologous recombination DNA-repair pathway
in human cells, without the requirement for eliciting
double-stranded DNA breaks using exogenous nucleases,
to precisely engineer any DNA variation of choice into
any human cell line, including the introduction of subtle
point mutations and single nucleotide polymorphisms
(SNPs), just as they occur in real patients.
The ability to rapidly, accurately and stably engineer
human genomes without introducing confounding off-
target effects has the potential to transform the field of
functional genomics and the design of future targeted, or
personalized, therapies. Data will be presented highlight-
ing the use of GENESIS to create genetically defined
‘X-MAN’ (gene X, mutant and normal) human isogenic
cell-line pairs, which accurately model specific genetic
variations present in a defined cancer patient population,
and provide a matched normal genetic background for
reference, in key application areas. First, defining the
core phenotype driven by specific cancer genes; second,
profiling the activity and therapeutic window of novel
cancer therapies on specific target patient genotypes;
third, systematically de-orphaning the cancer genome
with next-generation’synthetically lethal’drug targets by
combining with RNA interference and chemical geno-
mics tools; and fourth, their use as gold-standard geno-
mic reference materials for benchmarking molecular
diagnostic assays and platforms.
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